Document Detail


ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
MedLine Citation:
PMID:  19060001     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To evaluate various validity aspects of four disease activity scores (ASDAS) for ankylosing spondylitis (AS) in comparison with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), its individual components and physician and patient global assessment of disease activity. METHODS: The analyses were performed in two cohorts of patients with AS: (1) the NOR-DMARD database which includes patients starting on a disease-modifying antirheumatic drug or tumour necrosis factor (TNF) blocker and (2) patients participating in double-blind placebo controlled randomised clinical trials with TNF blockers in four centres. Discrimination between patients with low versus high disease activity according to various definitions and between various levels of change were analysed as the standardised mean difference (difference in the group means divided by the pooled SD of the group means) and t score. RESULTS: The four ASDAS versions were highly discriminatory in differentiating patients with different levels of disease activity and patients with different levels of change. The ASDAS scores outperformed the BASDAI and its single components in all settings: patient- or physician-based, reflecting status or change, with normal or raised C-reactive protein (CRP), in the presence or absence of peripheral arthritis. There were no major differences between the four ASDAS scores. Based on feasibility, the ASAS membership selected the ASDAS version which included back pain, duration of morning stiffness, patient global assessment, peripheral joint complaints and CRP as the preferred version. CONCLUSIONS: The ASDAS is a validated, highly discriminatory instrument for assessing disease activity in AS, including patient-reported outcomes and CRP levels.
Authors:
D van der Heijde; E Lie; T K Kvien; J Sieper; F Van den Bosch; J Listing; J Braun; R Landew??;
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Validation Studies     Date:  2008-12-05
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  68     ISSN:  1468-2060     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-13     Completed Date:  2009-12-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  1811-8     Citation Subset:  IM    
Affiliation:
Department of Rheumatology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands. d.vanderheijde@kpnplanet.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antirheumatic Agents / therapeutic use*
Back Pain / etiology
Biological Markers / blood
C-Reactive Protein / analysis
Epidemiologic Methods
Female
Humans
Male
Middle Aged
Severity of Illness Index*
Spondylitis, Ankylosing / complications,  drug therapy*
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Antirheumatic Agents; 0/Biological Markers; 0/Tumor Necrosis Factor-alpha; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but no...
Next Document:  Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic lit...